vs

Side-by-side financial comparison of Anterix Inc. (ATEX) and DBV Technologies S.A. (DBVT). Click either name above to swap in a different company.

DBV Technologies S.A. is the larger business by last-quarter revenue ($2.8M vs $1.6M, roughly 1.8× Anterix Inc.). Anterix Inc. runs the higher net margin — -419.6% vs -1195.5%, a 775.9% gap on every dollar of revenue. On growth, DBV Technologies S.A. posted the faster year-over-year revenue change (158.8% vs 0.4%). Anterix Inc. produced more free cash flow last quarter ($-8.3M vs $-32.6M). Over the past eight quarters, DBV Technologies S.A.'s revenue compounded faster (12.4% CAGR vs 11.7%).

Anterix Inc. is a U.S.-headquartered wireless communications company that owns licensed 900 MHz spectrum assets, providing secure, dedicated private broadband network solutions for critical infrastructure operators including electric utilities, public safety agencies, and transportation providers. Its primary market is North America, supporting clients requiring highly reliable connectivity for mission-critical operations.

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.

ATEX vs DBVT — Head-to-Head

Bigger by revenue
DBVT
DBVT
1.8× larger
DBVT
$2.8M
$1.6M
ATEX
Growing faster (revenue YoY)
DBVT
DBVT
+158.3% gap
DBVT
158.8%
0.4%
ATEX
Higher net margin
ATEX
ATEX
775.9% more per $
ATEX
-419.6%
-1195.5%
DBVT
More free cash flow
ATEX
ATEX
$24.3M more FCF
ATEX
$-8.3M
$-32.6M
DBVT
Faster 2-yr revenue CAGR
DBVT
DBVT
Annualised
DBVT
12.4%
11.7%
ATEX

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
ATEX
ATEX
DBVT
DBVT
Revenue
$1.6M
$2.8M
Net Profit
$-6.6M
$-33.2M
Gross Margin
Operating Margin
-576.0%
-1235.7%
Net Margin
-419.6%
-1195.5%
Revenue YoY
0.4%
158.8%
Net Profit YoY
-185.6%
-8.9%
EPS (diluted)
$-0.35
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATEX
ATEX
DBVT
DBVT
Q4 25
$1.6M
Q3 25
$1.6M
$2.8M
Q2 25
$1.4M
$1.5M
Q1 25
$1.4M
Q4 24
$1.6M
Q3 24
$1.6M
Q2 24
$1.5M
$1.2M
Q1 24
$1.3M
$1.4M
Net Profit
ATEX
ATEX
DBVT
DBVT
Q4 25
$-6.6M
Q3 25
$53.5M
$-33.2M
Q2 25
$25.2M
$-41.9M
Q1 25
$9.2M
Q4 24
$7.7M
Q3 24
$-12.8M
Q2 24
$-15.5M
$-33.1M
Q1 24
$-9.4M
$-27.3M
Operating Margin
ATEX
ATEX
DBVT
DBVT
Q4 25
-576.0%
Q3 25
-1235.7%
Q2 25
-2806.2%
Q1 25
Q4 24
Q3 24
-846.6%
Q2 24
-984.4%
-2914.9%
Q1 24
-834.2%
-2029.7%
Net Margin
ATEX
ATEX
DBVT
DBVT
Q4 25
-419.6%
Q3 25
3449.5%
-1195.5%
Q2 25
1775.7%
-2858.4%
Q1 25
662.9%
Q4 24
492.3%
Q3 24
-823.1%
Q2 24
-1018.0%
-2852.4%
Q1 24
-746.9%
-1943.5%
EPS (diluted)
ATEX
ATEX
DBVT
DBVT
Q4 25
$-0.35
Q3 25
$2.86
$-0.24
Q2 25
$1.35
$-0.31
Q1 25
$0.51
Q4 24
$0.41
Q3 24
$-0.69
Q2 24
$-0.84
$-0.34
Q1 24
$-0.51
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATEX
ATEX
DBVT
DBVT
Cash + ST InvestmentsLiquidity on hand
$29.5M
$69.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$236.0M
$52.9M
Total Assets
$417.0M
$110.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATEX
ATEX
DBVT
DBVT
Q4 25
$29.5M
Q3 25
$39.1M
$69.8M
Q2 25
$41.4M
$103.2M
Q1 25
$47.4M
Q4 24
$28.8M
Q3 24
$43.1M
Q2 24
$51.7M
$66.2M
Q1 24
$60.6M
$101.5M
Stockholders' Equity
ATEX
ATEX
DBVT
DBVT
Q4 25
$236.0M
Q3 25
$240.3M
$52.9M
Q2 25
$184.8M
$86.2M
Q1 25
$156.6M
Q4 24
$144.7M
Q3 24
$139.1M
Q2 24
$148.8M
$79.1M
Q1 24
$161.0M
$111.7M
Total Assets
ATEX
ATEX
DBVT
DBVT
Q4 25
$417.0M
Q3 25
$420.4M
$110.5M
Q2 25
$359.6M
$143.4M
Q1 25
$333.1M
Q4 24
$326.7M
Q3 24
$317.2M
Q2 24
$321.1M
$114.2M
Q1 24
$324.9M
$145.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATEX
ATEX
DBVT
DBVT
Operating Cash FlowLast quarter
$-8.3M
$-32.4M
Free Cash FlowOCF − Capex
$-8.3M
$-32.6M
FCF MarginFCF / Revenue
-526.4%
-1173.5%
Capex IntensityCapex / Revenue
0.6%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-138.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATEX
ATEX
DBVT
DBVT
Q4 25
$-8.3M
Q3 25
$1.4M
$-32.4M
Q2 25
$-3.1M
$-33.9M
Q1 25
$-16.6M
Q4 24
$-7.7M
Q3 24
$-2.6M
Q2 24
$-2.4M
$-35.1M
Q1 24
$6.1M
$-34.7M
Free Cash Flow
ATEX
ATEX
DBVT
DBVT
Q4 25
$-8.3M
Q3 25
$-32.6M
Q2 25
$-33.9M
Q1 25
$-16.6M
Q4 24
Q3 24
$-2.7M
Q2 24
$-35.8M
Q1 24
$6.1M
$-36.0M
FCF Margin
ATEX
ATEX
DBVT
DBVT
Q4 25
-526.4%
Q3 25
-1173.5%
Q2 25
-2316.5%
Q1 25
-1195.2%
Q4 24
Q3 24
-173.4%
Q2 24
-3084.0%
Q1 24
484.1%
-2560.6%
Capex Intensity
ATEX
ATEX
DBVT
DBVT
Q4 25
0.6%
Q3 25
4.2%
Q2 25
2.2%
Q1 25
3.3%
Q4 24
0.0%
Q3 24
2.6%
Q2 24
0.0%
63.0%
Q1 24
3.2%
94.9%
Cash Conversion
ATEX
ATEX
DBVT
DBVT
Q4 25
Q3 25
0.03×
Q2 25
-0.12×
Q1 25
-1.80×
Q4 24
-1.00×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons